These data taken together indicate that HLA-I+/PD-L1– expression pattern is favorable for tumor rejection, while HLA-I–/PD-L1+ phenotype is more aggressive from the immunological point of view and can be responsible for the resistance to immune checkpoint therapy in patients with high tumor PD-L1 expression [28]. This evidence concerns the gene CD274 and neoplasm.